comparison of the effects of enoxaparin and heparin on inflammatory biomarkers in patients with st-segment elevated myocardial infarction: a prospective open label pilot clinical trial

objective: heparin and enoxaparin possess anti-inflammatory properties. we compared the effects of these drugs on inflammatory biomarkers in patients with st-segment elevated myocardial infarction (stemi). method: thirty four patients with stemi randomly separated in two groups and received standard doses of heparin and enoxaparin. the serum concentration of serum amyloid a (saa), c-reactive protein (crp), interleukin (il)-6, ferritin and myeloperoxidase(mpo) were measured at baseline ,12 ,24 and 48 hours after drug administration. results: serum concentrations of saa (p: 0.02), crp (p: 0.02) and ferritin (p: 0.01) significantly reduced in heparin group during measurements compared to baseline, circulating levels of il-6 (p: 0.002), saa (p: 0.009), crp (p: 0.01) were significantly decreased in enoxaparin group. the overall difference in inflammatory biomarkers between heparin and enoxaparin group was not significant. conclusion: both heparin and enoxaparine reduced serum levels of inflammatory biomarkers in patients with stemi. this effect may provide additional clinical benefit of these drugs in the treatment of stemi patients.